Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 12 December 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1761643

Correction: Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer

This article is a correction to:

  1. Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer

    1. Read original article
Frontiers Production Office* Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

A Correction on
Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer

By Zou L, Chen J, Bai X, Wang Y, Lu C, Wang Q, Tuerhong S, Li M, Zheng Q, Meng F and Du J (2025) Front. Immunol. 16:1693755. doi: 10.3389/fimmu.2025.1693755

The Editor Christian Klein’s affiliation “Ludwig Maximilian University of Munich, Germany” was erroneously given as “Roche Innovation Center Zurich, Switzerland”.

The original version of this article has been updated.

Keywords: KRAS G12V, bispecific T-cell engager (BiTE), IRGD, pancreatic cancer, T-cell infiltration

Citation: Frontiers Production Office (2025) Correction: Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer. Front. Immunol. 16:1761643. doi: 10.3389/fimmu.2025.1761643

Received: 05 December 2025; Accepted: 05 December 2025;
Published: 12 December 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.